How Mindray’s BC-6800Plus Raises the Floor for Routine Hematology Lab Throughput

Mindray BC-6800Plus 5-Part Differential Hematology Analyzer

Most clinical labs in China and across emerging markets run on a simple calculus: more tests per shift means lower cost per result. The Mindray BC-6800Plus, rated at up to 200 tests per hour with a 5-part white blood cell differential, is a machine built for that equation. It handles CBCs, reticulocyte counts, and nucleated red blood cell analysis in a single pass, without requiring additional reagents for the latter — a workflow detail that matters more in practice than in spec sheets.

What distinguishes the BC-6800Plus from earlier generations is not raw speed alone but the integration of SF Cube technology and fluorescent staining within a single optical path. This allows the instrument to differentiate cell populations — particularly abnormal cells — with greater precision. For a lab technician in a mid-tier hospital in Guangdong or a diagnostic center in Istanbul, that translates into fewer manual slides and fewer reruns.

The system can load up to 100 samples simultaneously and includes automatic rerun and reflex testing functions. Reflex testing — where results from one parameter trigger follow-up tests — is particularly valuable when the lab does not have a dedicated specialist reviewing every result in real time. The analyzer also automatically computes the neutrophil-to-lymphocyte ratio, a biomarker increasingly used in inflammation and infection monitoring.

Mindray’s position in this market is instructive. The Shenzhen-based company competes directly with Siemens, Abbott, and Sysmex, but it does so by offering comparable specification profiles at prices that undercut the incumbents by 20 to 30 percent. The BC-6800Plus is not a breakthrough instrument in the sense of introducing a novel detection principle — it is a well-integrated, mid- to high-throughput platform optimized for price-performance.

That pricing strategy has real consequences. For procurement managers in large hospital groups and regional lab chains, the machine represents a way to standardize blood analysis across multiple sites without ballooning capital expenditure. It also makes the latest 5-part differential technology accessible to laboratories that previously relied on older 3-part machines — a meaningful upgrade for rural China and parts of Southeast Asia.

The broader trend here is not about a single analyzer but about how Chinese medtech manufacturers have learned to compete: by squeezing cost out of production while matching the feature set of global leaders. Mindray’s ability to combine fluorescence-based reticulocyte measurement, NRBC detection, and automated reflex testing in a single chassis reflects a supply chain that is increasingly capable of producing complex in vitro diagnostics hardware at scale.

What the BC-6800Plus signals is that the gap between “good enough” and “best in class” in routine hematology has narrowed significantly — and that the narrowing is being driven from Shenzhen, not Munich or Tokyo.

Why it matters:
For labs looking to upgrade throughput without replacing their entire infrastructure, the BC-6800Plus offers a clear path. It also underscores a broader shift: Chinese diagnostics firms are no longer competing on price alone — they are matching feature-for-feature in categories that require real optical engineering and clinical validation.

View Product →